Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
about
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?G protein-coupled receptor heterocomplexes in neuropsychiatric disorders.Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family.Re-exploring the N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved affinity and in vitro microsomal stability.Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled ReceptorsThe antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodentsMetabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012).Novel thiazole derivatives: a patent review (2008 - 2012. Part 2).Insights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes.Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist.Metabotropic glutamate receptors for Parkinson's disease therapy.Co-operative binding assay for the characterization of mGlu4 allosteric modulators.Synthesis and evaluation of N-(methylthiophenyl)picolinamide derivatives as PET radioligands for metabotropic glutamate receptor subtype 4.Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors – A Structural Perspective of Ligands and Mutants.
P2860
Q27021464-25B20946-89C0-42F9-ACFE-272A755518C8Q30385233-083E7FAB-9EC9-49EC-8D7E-FCBA24D7D175Q34399823-88624E9C-DB52-428A-990C-4CDA38430A44Q35529175-021BB012-EDE6-49D9-A3F1-997EEF816D6AQ35964194-4369A0B8-3427-4196-A99A-74396361A439Q35967903-2EE58365-859E-4142-89D0-C1D5C7F6680EQ37122707-A44D22F4-DEE7-4CFE-AD10-3BBF4794D299Q38162957-6AC3DE61-C9B4-4F5B-A298-2C459978DC96Q38205485-F9CC3191-57E9-4F3A-BD64-4A7104CEF6B9Q38247995-C2C71ABF-FBCF-4AE6-9AA4-3A98C1F0204CQ39782221-C45534FF-426B-4FBB-9616-547CAF963986Q41818450-30C23889-96D9-46B0-9CDE-04ED2EA5A209Q41887461-467E94C5-0144-457E-8987-2D2177003916Q42092185-9CD7572A-BD58-4476-998A-C675F7B72309Q43193327-616942C7-B6CB-41B1-B70E-AE90D6011D3E
P2860
Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Metabotropic glutamate recepto ...... view of the patent literature.
@en
type
label
Metabotropic glutamate recepto ...... view of the patent literature.
@en
prefLabel
Metabotropic glutamate recepto ...... view of the patent literature.
@en
P2860
P1476
Metabotropic glutamate recepto ...... view of the patent literature.
@en
P2093
Corey R Hopkins
P2860
P304
P356
10.1517/13543776.2012.679437
P407
P577
2012-04-16T00:00:00Z